Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy
Copyright © 2024 American Society of Hematology..
Teclistamab (Tec) is a first-in-class BCMA X CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study was to evaluate the rate of cytokine release syndrome (CRS) in patients who were treated with commercial Tec and had prior exposure to other T-cell redirection therapies. A retrospective chart review was performed to identify patients who completed the Tec step-up dosing phase between November 2022 and November 2023. Patients were divided into 2 cohorts based on prior exposure to T-cell redirection therapy (cohort 1: T-cell redirection therapy experienced; cohort 2: T-cell redirection therapy naïve). The primary objective was to compare the differences in the rates of CRS between the two cohorts. Univariate and multivariate logistic regression analyses were performed to assess the association between CRS rates with Tec and prior treatment with T-cell redirection therapy. A total of 72 patients were included in the analysis (27 in cohort 1 and 45 in cohort 2). The CRS rates were significantly lower in cohort 1 (37%, n=10) compared to cohort 2 (80%, n=36; p=0.0004). Based on multivariate logistic regression analysis, patients without prior exposure to T-cell redirection therapy (cohort 2) had about a 4-fold increase in the incidence of CRS (95% CI: 1.40-14.90, p=0.0002) with Tec. In our study, prior exposure to T-cell redirection therapy reduced the risk of CRS with Tec during the step-up dosing phase. This observation will allow for the optimization of CRS prophylactic strategies for Tec.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Blood advances - (2024) vom: 10. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hamadeh, Issam S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1182/bloodadvances.2024012724 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370880412 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370880412 | ||
| 003 | DE-627 | ||
| 005 | 20240411233101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2024012724 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM370880412 | ||
| 035 | |a (NLM)38598713 | ||
| 035 | |a (PII)bloodadvances.2024012724 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hamadeh, Issam S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 American Society of Hematology. | ||
| 520 | |a Teclistamab (Tec) is a first-in-class BCMA X CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study was to evaluate the rate of cytokine release syndrome (CRS) in patients who were treated with commercial Tec and had prior exposure to other T-cell redirection therapies. A retrospective chart review was performed to identify patients who completed the Tec step-up dosing phase between November 2022 and November 2023. Patients were divided into 2 cohorts based on prior exposure to T-cell redirection therapy (cohort 1: T-cell redirection therapy experienced; cohort 2: T-cell redirection therapy naïve). The primary objective was to compare the differences in the rates of CRS between the two cohorts. Univariate and multivariate logistic regression analyses were performed to assess the association between CRS rates with Tec and prior treatment with T-cell redirection therapy. A total of 72 patients were included in the analysis (27 in cohort 1 and 45 in cohort 2). The CRS rates were significantly lower in cohort 1 (37%, n=10) compared to cohort 2 (80%, n=36; p=0.0004). Based on multivariate logistic regression analysis, patients without prior exposure to T-cell redirection therapy (cohort 2) had about a 4-fold increase in the incidence of CRS (95% CI: 1.40-14.90, p=0.0002) with Tec. In our study, prior exposure to T-cell redirection therapy reduced the risk of CRS with Tec during the step-up dosing phase. This observation will allow for the optimization of CRS prophylactic strategies for Tec | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Shekarkhand, Tala |e verfasserin |4 aut | |
| 700 | 1 | |a Rueda, Colin Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Firestone, Ross S |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Alice X |e verfasserin |4 aut | |
| 700 | 1 | |a Korde, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Hultcrantz, Malin L |e verfasserin |4 aut | |
| 700 | 1 | |a Lesokhin, Alexander M |e verfasserin |4 aut | |
| 700 | 1 | |a Mailankody, Sham |e verfasserin |4 aut | |
| 700 | 1 | |a Hassoun, Hani |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Urvi A |e verfasserin |4 aut | |
| 700 | 1 | |a Maclachlan, Kylee H |e verfasserin |4 aut | |
| 700 | 1 | |a Rajeeve, Sridevi |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Dhwani |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Gunjan L |e verfasserin |4 aut | |
| 700 | 1 | |a Scordo, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Lahoud, Oscar B |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Landau, Heather J |e verfasserin |4 aut | |
| 700 | 1 | |a Giralt, Sergio A |e verfasserin |4 aut | |
| 700 | 1 | |a Usmani, Saad Z |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Carlyn Rose |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g (2024) vom: 10. Apr. |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2024012724 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 04 | ||